

MSH6 syndrome

Janina Suchy, Jan Lubiński

International Hereditary Cancer Centre, Department of Genetics and Pathology, Szczecin, Poland

Corresponding author: Janina Suchy, International Hereditary Cancer Centre, Department of Genetics and Pathology, Pomeranian Medical University, Połabska 4, 70-115 Szczecin, Poland, e-mail: jsuchy@sci.pam.szczecin.pl

The *MSH6* gene in collaboration with *MSH2*, *MLH1*, *MSH3*, *PMS1* and *PMS2* genes is involved in one of the systems repairing the errors that arise during DNA replication, called the "methyl directed mismatch repair" system [1-3]. *hMLH1* and *hMSH2* mutations give rise most frequently to the classical Lynch syndrome (HNPCC) [4-6]. *hMSH6* mutations often occur in clinically less typical HNPCC families, that do not fulfil the Amsterdam criteria [7-11]. So far more than 200 families with germline *hMSH6* mutation have been described (www.med.ca/MMRvariants).

Characteristic features of families with *hMSH6* mutation are:

- higher risk for colorectal cancer (~70% for men and ~30% for females), endometrial cancer (~70%) and also for ovarian, upper urinary tract, stomach and breast cancer [12],
- higher incidence of extracolonic cancers, when compared with HNPCC families [13],
- later age at onset of cancers, e.g. for colorectal cancer the mean age at diagnosis is ~56 years, for endometrial cancer ~54 years and for ovarian cancer ~49 years [12, 13],
- frequent left-sided localization of colorectal cancer [9].

The prevalence of *hMSH6* constitutional mutations in families that fulfil the Amsterdam criteria is about 5-10% [8, 9].

Because the frequency of *hMSH6* mutations in other groups is not precisely determined, we recommend the following diagnostic procedure for *hMSH6* mutation detection:

- selection of families with colorectal, endometrial, ovarian, urinary tract and/or stomach, breast cancer aggregation,
- immunohistochemical analysis (IHC) of *hMSH6* protein expression in tumour colorectal or endometrial tissue [14-16],
- in cases of *hMSH6*-negative tumours, DHPLC/sequencing of the coding regions of the *hMSH6* gene.

Among the reported *hMSH6* mutations about 30 are recurrent, i.e. they are detected in more than one family [17-19]. Probably in the near future diagnostic tests will be described to allow cheap, simple and fast detection of mutations showing a "founder effect" characteristic for particular ethnic groups.

Surveillance protocol

As yet a suitable surveillance programme in *hMSH6* families based on prospective family trials is not available. In our centre we offer the following surveillance protocol:

- colorectal cancer – colonoscopy every 2 to 3 years beginning at least 15 years before the earliest age of onset in the family,
- endometrial cancer – annual transvaginal ultrasound scan starting at least 15 years before the earliest age of onset in the family,
- screening for other cancers depending on the tumour spectrum in the family.

Surgical management

Because of the described higher risk of developing multiple (synchronous and metachronous) cancers and also endometrial cancer in females after age of 50 years in *hMSH6* mutation carriers [12, 17, 20], it is recommended to take into consideration surgical treatment similar to that for patients with CRC associated with Lynch syndrome, i.e. colectomy with ileorectal anastomosis, extended by prophylactic hysterectomy and oophorectomy for women over 50 years old.

References:

1. Fleck O, Nielsen O. DNA repair. *J Cell Sci* 2004; 117: 515-517.
2. Pinto LA, Regis da Silva CG, Lopes D, Machado-Silva A, Machado CR. *Escherichia coli* as a model system to study DNA repair genes of eukaryotic organisms. *Genetics Mol Res* 2003; 2: 77-91.

3. Marti T, Kunz C, Fleck O. DNA mismatch repair and mutation avoidance pathways. *J Cell Physiol* 2002; 191: 28-41.
4. Abdel-Rahman WM, Mecklin JP, Peltomäki P. The genetics of HNPCC: application to diagnosis and screening. *Crit Rev Oncol Hematol* 2006; 58: 208-220.
5. Lagerstedt Robinson K, Liu T, Vandrovцова J, Halvarsson B, Clendenning M, Frebourg T, Papadopoulos N, Kinzler KW, Vogelstein B, Peltomäki P, Kolodner RD, Nilbert M, Lindblom A. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. *J Natl Cancer Inst* 2007; 99: 291-299.
6. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. *J Med Genet* 1999; 36: 801-818.
7. Wagner A, Hendriks Y, Meijers-Heijboer EJ, de Leeuw WJ, Morreau H, Hofstra R, Tops C, Bik E, Bröcker-Vriends AH, van Der Meer C, Lindhout D, Vasen HF, Breuning MH, Cornelisse CJ, van Krimpen C, Niermeijer MF, Zwinderman AH, Wijnen J, Fodde R. Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree. *J Med Genet* 2001; 38: 318-332.
8. Roncari B, Pedroni M, Maffei S, Di Gregorio C, Ponti G, Scarselli A, Losi L, Benatti P, Roncucci L, De Gaetani C, Camellini L, Lucci-Cordisco E, Tricarico R, Genuardi M, Ponz de Leon M. Frequency of constitutional MSH6 mutations in a consecutive series of families with the clinical suspicion of HNPCC. *Clin Genet* 2007; 72: 230-237.
9. Berends MJ, Wu Y, Sijmons RH, Mensink RG, van der Sluis T, Hordijk-Hos JM, de Vries EG, Hollema H, Karrenbeld A, Buys CH, van der Zee AG, Hofstra RM, Kleibeuker JH. Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. *Am J Hum Genet* 2002; 70: 26-37.
10. Suchy J, Kurzawski G, Jakubowska A, Lubiński J. Ovarian cancer of endometrioid type as part of the MSH6 gene mutation phenotype. *J Hum Genet* 2002; 47: 529-531.
11. Suchy J, Kurzawski G, Jakubowska K, Rać ME, Safranow K, Kładny J, Rzepka-Górska I, Chosia M, Czeszyńska B, Oszurek O, Scott RJ, Lubiński J. Frequency and nature of hMSH6 germline mutations in Polish patients with colorectal, endometrial and ovarian cancers. *Clin Genet* 2006; 70: 68-70.
12. Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger F, Sandkuijl L, Møller P, Genuardi M, Van Houwelingen H, Tops C, Van Puijtenbroek M, Verkuijlen P, Kenter G, Van Mil A, Meijers-Heijboer H, Tan GB, Breuning MH, Fodde R, Wijnen JT, Bröcker-Vriends AH, Vasen H. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. *Gastroenterology* 2004; 127: 17-25.
13. Plaschke J, Engel C, Krüger S, Holinski-Feder E, Pagenstecher C, Mangold E, Moeslein G, Schulmann K, Gebert J, von Knebel Doeberitz M, Rüschoff J, Loeffler M, Schackert HK. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. *J Clin Oncol* 2004; 22: 4486-4494.
14. Rigau V, Sebbagh N, Olschwang S, Paraf F, Mourra N, Parc Y, Flejou JF. Microsatellite instability in colorectal carcinoma. The comparison of immunohistochemistry and molecular biology suggests a role for hMSH6 [correction of hMLH6] immunostaining. *Arch Pathol Lab Med* 2003; 127: 694-700.
15. Plaschke J, Krüger S, Pistorius S, Theissig F, Saeger H, Schackert H. Involvement of hMSH6 in the development of hereditary and sporadic colorectal cancer revealed by immunostaining is based on germline mutations, but rarely on somatic inactivation. *Int J Cancer* 2002; 97: 643-648.
16. Plaschke J, Krüger S, Dietmaier W, Gebert J, Sutter C, Mangold E, Pagenstecher C, Holinski-Feder E, Schulmann K, Moeslein G, Rüschoff J, Engel C, Evans G, Schackert HK; German HNPCC Consortium. Eight novel MSH6 germline mutations in patients with familial and nonfamilial colorectal cancer selected by loss of protein expression in tumor tissue. *Hum Mut* 2004; 23: 285.
17. Cederquist K, Emanuelsson M, Göransson I, Holinski-Feder E, Müller-Koch Y, Golovleva I, Grönberg H. Mutation analysis of the MLH1, MSH2 and MSH6 genes in patients with double primary cancers of the colorectum and the endometrium: a population-based study in northern Sweden. *Int J Cancer* 2004; 109: 370-376.
18. Wu Y, Berends MJ, Mensink RG, Kempinga C, Sijmons RH, van Der Zee AG, Hollema H, Kleibeuker JH, Buys CH, Hofstra RM. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. *Am J Hum Genet* 1999; 65: 1291-1298.
19. Shin KH, Ku JL, Park JG. Germline mutations in a polycytosine repeat of the hMSH6 gene in Korean hereditary nonpolyposis colorectal cancer. *J Hum Genet* 1999; 44: 18-21.
20. Charames GS, Millar AL, Pal T, Narod S, Bapat B. Do MSH6 mutations contribute to double primary cancers of the colorectum and endometrium? *Hum Genet* 2000; 107: 623-629.